Cargando…
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
BACKGROUND: Elevated vascular endothelial growth factor (VEGF) was associated with poor prognosis in leptomeningeal carcinomatosis and anti-angiogenic therapy was found to prolong the survival of mice in preclinical studies. This prospective pilot study investigated the efficacy of anti-VEGF therapy...
Autores principales: | Wu, Pei-Fang, Lin, Ching-Hung, Kuo, Ching-Hua, Chen, Wei-Wu, Yeh, Dah-Cherng, Liao, Hsiao-Wei, Huang, Shu-Min, Cheng, Ann-Lii, Lu, Yen-Shen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403836/ https://www.ncbi.nlm.nih.gov/pubmed/25928457 http://dx.doi.org/10.1186/s12885-015-1290-1 |
Ejemplares similares
-
Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival
por: Chen, Tom Wei-Wu, et al.
Publicado: (2020) -
Recent Advancements of Treatment for Leptomeningeal Carcinomatosis
por: Gwak, Ho-Shin, et al.
Publicado: (2015) -
Leptomeningeal Carcinomatosis with Delayed Ocular Manifestations
por: Czyz, Craig, et al.
Publicado: (2021) -
Leptomeningeal carcinomatosis or ischemic cerebrovascular disease?
por: Eran, Ayelet, et al.
Publicado: (2021) -
Leptomeningeal carcinomatosis associated with papillary renal cell carcinoma
por: Chilkulwar, Abhishek, et al.
Publicado: (2014)